Japan reportedly is considering a change in its drug-pricing policy, setting price caps that would last for three fiscal years instead of the current two.
It took a U.S. jury only two hours to decide to assess Takeda Pharmaceutical $1.3 million in punitive damages for the bladder cancer it ruled earlier were caused by Actos (pioglitazone) diabetes drug.
An outbreak of the H1N1A influenza--once known as "swine flu"--has led to a run on generic drugs relied on for treatment, prompting the government to urge local makers to step up production.
China and U.S. drug officials held their first working meeting of the year recently, China's FDA revealed.
Eisai grabbed an early green light on Friday from U.S. regulators for thyroid cancer drug Lenvima, meaning the Japanese pharma can now get an earlier-than-expected start on trying to make its blockbuster dreams a reality.
Industry-watchers knew a shake-up could be in Ariad Pharmaceuticals' future when Alex Denner, founder of activist hedge fund Sarissa Capital and protégé of notorious corporate raider Carl Icahn, took a seat on the company's board of directors last year. Now, a proxy brawl looks to be around the corner.
Eisai is counting on its new cancer drug to eventually bring in more than $1 billion a year, and now, thanks to an early FDA approval, the Japanese drugmaker has a head start on making that a reality.
Australia's Senate has passed two-year-old legislation that would afford drugmakers a bit of compulsory licensing and allow them to share patent application reviews and approvals with New Zealand, the decision of one being the decision of the other.
Teva has been investigating for some time whether its business practices abroad have breached the Foreign Corrupt Practices Act (FCPA) and/or local laws. And now, it says it's "likely" they have.
Behind the usual pharma scenes is a network of doctors, small drugmakers and distributors hawking new dosages of old drugs, a practice that allows physicians to dispense them and reap the profits by billing insurers directly.